Published online May 1, 2006
PEDIATRICS Vol. 117 No. 5 May 2006, pp. 1863-1864 (doi:10.1542/peds.2006-0133)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Related articles in Pediatrics
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sperandio, M.
Right arrow Articles by Linderkamp, O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sperandio, M.
Right arrow Articles by Linderkamp, O.
Related Collections
Right arrow Premature & Newborn

High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?: In Reply

Markus Sperandio, MD
Bernd Beedgen, MD
Otwin Linderkamp, MD
Division of Neonatal Medicine
Department of Pediatrics
University of Heidelberg
69120 Heidelberg, Germany

The first 20% of the full text of this article appears below.

In Reply.—

We appreciate Dr Manzar's comments on our high-dose indomethacin treatment strategy for the closure of symptomatic patent ductus arteriosus (sPDA) in premature infants1 and thank the editor for the opportunity to reply. Our initial rationale for treating infants suffering from sPDA with high doses of indomethacin was based less on reports that overdosages of indomethacin did not lead to severe adverse effects and more on the opportunity to . . . [Full Text of this Article]


Related articles in Pediatrics:

High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?
Shabih Manzar
Pediatrics 2006 117: 1863. [Extract] [Full Text]